Which has preferable valuation and earnings, DRMA or PTIX?

Dermata Therapeutics is trading at a lower price-to-earnings ratio than Atrinsic, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Dermata Therapeutics N/A N/A -$7.56M -$5.31 N/A Atrinsic N/A N/A -$5.53M -$3.45 N/A

Is DRMA or PTIX more profitable?

Atrinsic's return on equity of 0.00% beat Dermata Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Dermata Therapeutics N/A -127.91% -105.05% Atrinsic N/A N/A -379.72%

Do analysts recommend PTIX or RDHL?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Atrinsic 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Redhill Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings and valuation, PTIX or RDHL?

Redhill Biopharma has higher revenue and earnings than Atrinsic. Atrinsic is trading at a lower price-to-earnings ratio than Redhill Biopharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Atrinsic N/A N/A -$5.53M -$3.45 N/A Redhill Biopharma $290K 14.51 -$430K $1.05 thousand 0.00

Is PTIX or RDHL more profitable?

Company Net Margins Return on Equity Return on Assets Atrinsic N/A N/A -379.72% Redhill Biopharma N/A N/A N/A

Do analysts prefer ALZN or PTIX?

Alzamend Neuro presently has a consensus price target of $28.00, suggesting a potential upside of 2,178.28%. Given Alzamend Neuro's stronger consensus rating and higher probable upside, equities research analysts clearly believe Alzamend Neuro is more favorable than Atrinsic. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alzamend Neuro 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Atrinsic 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings & valuation, ALZN or PTIX?

Alzamend Neuro is trading at a lower price-to-earnings ratio than Atrinsic, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alzamend Neuro N/A N/A -$4.51M -$2.16 N/A Atrinsic N/A N/A -$5.53M -$3.45 N/A

Is ALZN or PTIX more profitable?

Atrinsic's return on equity of 0.00% beat Alzamend Neuro's return on equity. Company Net Margins Return on Equity Return on Assets Alzamend Neuro N/A -177.52% -140.41% Atrinsic N/A N/A -379.72%

Do analysts recommend PTIX or GOVX?

GeoVax Labs has a consensus target price of $150.00, suggesting a potential upside of 12,296.69%. Given GeoVax Labs' stronger consensus rating and higher probable upside, analysts plainly believe GeoVax Labs is more favorable than Atrinsic. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Atrinsic 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 GeoVax Labs 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Is PTIX or GOVX more profitable?

Atrinsic's return on equity of 0.00% beat GeoVax Labs' return on equity. Company Net Margins Return on Equity Return on Assets Atrinsic N/A N/A -379.72% GeoVax Labs N/A -709.52% -399.33%

Do analysts prefer GRI or PTIX?

GRI Bio currently has a consensus target price of $32.00, indicating a potential upside of 1,296.16%. Given GRI Bio's stronger consensus rating and higher probable upside, research analysts clearly believe GRI Bio is more favorable than Atrinsic. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GRI Bio 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Atrinsic 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings & valuation, GRI or PTIX?

Atrinsic is trading at a lower price-to-earnings ratio than GRI Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GRI Bio N/A N/A -$11.96M -$74.16 N/A Atrinsic N/A N/A -$5.53M -$3.45 N/A

Is GRI or PTIX more profitable?

Atrinsic's return on equity of 0.00% beat GRI Bio's return on equity. Company Net Margins Return on Equity Return on Assets GRI Bio N/A -199.52% -143.23% Atrinsic N/A N/A -379.72%

Atrinsic (PTIX) Competitors

$0.40 -0.10 (-19.92%)

As of 10:11 AM Eastern

Compare

PTIX vs. DRMA, RDHL, ALZN, GOVX, and GRI

Should you buy Atrinsic stock or one of its competitors? MarketBeat compares Atrinsic with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Atrinsic include Dermata Therapeutics (DRMA), Redhill Biopharma (RDHL), Alzamend Neuro (ALZN), GeoVax Labs (GOVX), and GRI Bio (GRI). These companies are all part of the "pharmaceutical products" industry.

How does Atrinsic compare to Dermata Therapeutics?

Dermata Therapeutics (NASDAQ:DRMA) and Atrinsic (NASDAQ:PTIX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, dividends, valuation, institutional ownership and media sentiment.

Dermata Therapeutics currently has a consensus target price of $10.00, indicating a potential upside of 736.12%. Given Dermata Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Dermata Therapeutics is more favorable than Atrinsic.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dermata Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Atrinsic	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

8.7% of Dermata Therapeutics shares are held by institutional investors. Comparatively, 8.0% of Atrinsic shares are held by institutional investors. 21.9% of Dermata Therapeutics shares are held by company insiders. Comparatively, 8.0% of Atrinsic shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Dermata Therapeutics has a beta of 0.69, indicating that its stock price is 31% less volatile than the broader market. Comparatively, Atrinsic has a beta of 1.01, indicating that its stock price is 1% more volatile than the broader market.

Atrinsic's return on equity of 0.00% beat Dermata Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dermata Therapeutics	N/A	-127.91%	-105.05%
Atrinsic	N/A	N/A	-379.72%

In the previous week, Dermata Therapeutics had 1 more articles in the media than Atrinsic. MarketBeat recorded 1 mentions for Dermata Therapeutics and 0 mentions for Atrinsic. Dermata Therapeutics' average media sentiment score of 1.87 beat Atrinsic's score of 0.00 indicating that Dermata Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Dermata Therapeutics	Very Positive
Atrinsic	Neutral

Dermata Therapeutics is trading at a lower price-to-earnings ratio than Atrinsic, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dermata Therapeutics	N/A	N/A	-$7.56M	-$5.31	N/A
Atrinsic	N/A	N/A	-$5.53M	-$3.45	N/A

Summary

Dermata Therapeutics beats Atrinsic on 8 of the 13 factors compared between the two stocks.

How does Atrinsic compare to Redhill Biopharma?

Atrinsic (NASDAQ:PTIX) and Redhill Biopharma (NASDAQ:RDHL) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, media sentiment, institutional ownership, earnings, valuation and profitability.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atrinsic	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Redhill Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Redhill Biopharma has higher revenue and earnings than Atrinsic. Atrinsic is trading at a lower price-to-earnings ratio than Redhill Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atrinsic	N/A	N/A	-$5.53M	-$3.45	N/A
Redhill Biopharma	$290K	14.51	-$430K	$1.05 thousand	0.00

In the previous week, Redhill Biopharma had 4 more articles in the media than Atrinsic. MarketBeat recorded 4 mentions for Redhill Biopharma and 0 mentions for Atrinsic. Redhill Biopharma's average media sentiment score of 0.37 beat Atrinsic's score of 0.00 indicating that Redhill Biopharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Atrinsic	Neutral
Redhill Biopharma	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Atrinsic	N/A	N/A	-379.72%
Redhill Biopharma	N/A	N/A	N/A

Atrinsic has a beta of 1.01, meaning that its stock price is 1% more volatile than the broader market. Comparatively, Redhill Biopharma has a beta of 4.98, meaning that its stock price is 398% more volatile than the broader market.

8.0% of Atrinsic shares are held by institutional investors. Comparatively, 7.2% of Redhill Biopharma shares are held by institutional investors. 8.0% of Atrinsic shares are held by insiders. Comparatively, 6.8% of Redhill Biopharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Redhill Biopharma beats Atrinsic on 8 of the 10 factors compared between the two stocks.

How does Atrinsic compare to Alzamend Neuro?

Alzamend Neuro (NASDAQ:ALZN) and Atrinsic (NASDAQ:PTIX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, valuation, media sentiment, analyst recommendations, institutional ownership, profitability and earnings.

Atrinsic's return on equity of 0.00% beat Alzamend Neuro's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alzamend Neuro	N/A	-177.52%	-140.41%
Atrinsic	N/A	N/A	-379.72%

Alzamend Neuro presently has a consensus price target of $28.00, suggesting a potential upside of 2,178.28%. Given Alzamend Neuro's stronger consensus rating and higher probable upside, equities research analysts clearly believe Alzamend Neuro is more favorable than Atrinsic.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alzamend Neuro	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Atrinsic	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Alzamend Neuro is trading at a lower price-to-earnings ratio than Atrinsic, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alzamend Neuro	N/A	N/A	-$4.51M	-$2.16	N/A
Atrinsic	N/A	N/A	-$5.53M	-$3.45	N/A

49.6% of Alzamend Neuro shares are held by institutional investors. Comparatively, 8.0% of Atrinsic shares are held by institutional investors. 1.4% of Alzamend Neuro shares are held by insiders. Comparatively, 8.0% of Atrinsic shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Alzamend Neuro has a beta of 0.16, meaning that its stock price is 84% less volatile than the broader market. Comparatively, Atrinsic has a beta of 1.01, meaning that its stock price is 1% more volatile than the broader market.

In the previous week, Alzamend Neuro had 2 more articles in the media than Atrinsic. MarketBeat recorded 2 mentions for Alzamend Neuro and 0 mentions for Atrinsic. Alzamend Neuro's average media sentiment score of 0.93 beat Atrinsic's score of 0.00 indicating that Alzamend Neuro is being referred to more favorably in the media.

Company	Overall Sentiment
Alzamend Neuro	Positive
Atrinsic	Neutral

Summary

Alzamend Neuro beats Atrinsic on 9 of the 13 factors compared between the two stocks.

How does Atrinsic compare to GeoVax Labs?

Atrinsic (NASDAQ:PTIX) and GeoVax Labs (NASDAQ:GOVX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership, media sentiment and risk.

8.0% of Atrinsic shares are owned by institutional investors. Comparatively, 6.1% of GeoVax Labs shares are owned by institutional investors. 8.0% of Atrinsic shares are owned by insiders. Comparatively, 0.7% of GeoVax Labs shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, GeoVax Labs had 3 more articles in the media than Atrinsic. MarketBeat recorded 3 mentions for GeoVax Labs and 0 mentions for Atrinsic. GeoVax Labs' average media sentiment score of 0.54 beat Atrinsic's score of 0.00 indicating that GeoVax Labs is being referred to more favorably in the news media.

Company	Overall Sentiment
Atrinsic	Neutral
GeoVax Labs	Positive

GeoVax Labs has a consensus target price of $150.00, suggesting a potential upside of 12,296.69%. Given GeoVax Labs' stronger consensus rating and higher probable upside, analysts plainly believe GeoVax Labs is more favorable than Atrinsic.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atrinsic	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
GeoVax Labs	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Atrinsic has a beta of 1.01, meaning that its share price is 1% more volatile than the broader market. Comparatively, GeoVax Labs has a beta of 3.62, meaning that its share price is 262% more volatile than the broader market.

Atrinsic's return on equity of 0.00% beat GeoVax Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atrinsic	N/A	N/A	-379.72%
GeoVax Labs	N/A	-709.52%	-399.33%

Atrinsic has higher earnings, but lower revenue than GeoVax Labs. Atrinsic is trading at a lower price-to-earnings ratio than GeoVax Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atrinsic	N/A	N/A	-$5.53M	-$3.45	N/A
GeoVax Labs	$2.49M	1.69	-$21.47M	-$19.12	N/A

Summary

Atrinsic beats GeoVax Labs on 7 of the 13 factors compared between the two stocks.

How does Atrinsic compare to GRI Bio?

GRI Bio (NASDAQ:GRI) and Atrinsic (NASDAQ:PTIX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, profitability, earnings, analyst recommendations, valuation and institutional ownership.

Atrinsic's return on equity of 0.00% beat GRI Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GRI Bio	N/A	-199.52%	-143.23%
Atrinsic	N/A	N/A	-379.72%

Atrinsic is trading at a lower price-to-earnings ratio than GRI Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GRI Bio	N/A	N/A	-$11.96M	-$74.16	N/A
Atrinsic	N/A	N/A	-$5.53M	-$3.45	N/A

In the previous week, GRI Bio had 1 more articles in the media than Atrinsic. MarketBeat recorded 1 mentions for GRI Bio and 0 mentions for Atrinsic. GRI Bio's average media sentiment score of 1.87 beat Atrinsic's score of 0.00 indicating that GRI Bio is being referred to more favorably in the media.

Company	Overall Sentiment
GRI Bio	Very Positive
Atrinsic	Neutral

GRI Bio has a beta of -1.17, indicating that its share price is 217% less volatile than the broader market. Comparatively, Atrinsic has a beta of 1.01, indicating that its share price is 1% more volatile than the broader market.

GRI Bio currently has a consensus target price of $32.00, indicating a potential upside of 1,296.16%. Given GRI Bio's stronger consensus rating and higher probable upside, research analysts clearly believe GRI Bio is more favorable than Atrinsic.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GRI Bio	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Atrinsic	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

34.0% of GRI Bio shares are owned by institutional investors. Comparatively, 8.0% of Atrinsic shares are owned by institutional investors. 8.7% of GRI Bio shares are owned by company insiders. Comparatively, 8.0% of Atrinsic shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

GRI Bio beats Atrinsic on 9 of the 13 factors compared between the two stocks.

Get Atrinsic News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PTIX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PTIX vs. The Competition

Export

Metric	Atrinsic	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$724K	$3.40B	$6.50B	$12.37B
Dividend Yield	N/A	2.25%	2.67%	5.66%
P/E Ratio	-0.05	20.08	24.01	24.71
Price / Sales	N/A	326.19	540.55	165.59
Price / Cash	N/A	53.61	27.48	37.92
Price / Book	0.20	8.11	10.55	6.85
Net Income	-$5.53M	$23.89M	$3.56B	$337.45M
7 Day Performance	-24.01%	3.36%	1.54%	2.70%
1 Month Performance	-38.45%	1.34%	2.48%	4.60%
1 Year Performance	-87.95%	46.46%	26.49%	32.81%

Atrinsic Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PTIX Atrinsic	N/A	$0.40 -19.9%	N/A	-85.0%	$724K	N/A	N/A	2	Gap Up
DRMA Dermata Therapeutics	3.2304 of 5 stars	$1.22 +2.5%	$10.00 +719.7%	-83.4%	$4.90M	N/A	N/A	8	Gap Down
RDHL Redhill Biopharma	1.0099 of 5 stars	$0.92 +4.7%	N/A	-53.7%	$4.78M	$290K	0.00	210
ALZN Alzamend Neuro	3.8291 of 5 stars	$1.15 -1.3%	$28.00 +2,345.4%	-62.7%	$4.41M	N/A	N/A	4	Positive News
GOVX GeoVax Labs	2.4923 of 5 stars	$1.18 -1.7%	$150.00 +12,611.9%	-95.3%	$4.10M	$852.28K	N/A	10	Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PTIX) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Atrinsic (PTIX) Competitors

PTIX vs. DRMA, RDHL, ALZN, GOVX, and GRI

How does Atrinsic compare to Dermata Therapeutics?

Summary

How does Atrinsic compare to Redhill Biopharma?

Summary

How does Atrinsic compare to Alzamend Neuro?

Summary

How does Atrinsic compare to GeoVax Labs?

Summary

How does Atrinsic compare to GRI Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PTIX vs. The Competition

Atrinsic Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Atrinsic (PTIX) Competitors

PTIX vs. DRMA, RDHL, ALZN, GOVX, and GRI

How does Atrinsic compare to Dermata Therapeutics?

Do analysts recommend DRMA or PTIX?

Do institutionals and insiders have more ownership in DRMA or PTIX?

Which has more volatility and risk, DRMA or PTIX?

Is DRMA or PTIX more profitable?

Does the media prefer DRMA or PTIX?

Which has preferable valuation and earnings, DRMA or PTIX?

Summary

How does Atrinsic compare to Redhill Biopharma?

Do analysts recommend PTIX or RDHL?

Which has preferable earnings and valuation, PTIX or RDHL?

Does the media refer more to PTIX or RDHL?

Is PTIX or RDHL more profitable?

Which has more volatility & risk, PTIX or RDHL?

Do insiders & institutionals hold more shares of PTIX or RDHL?

Summary

How does Atrinsic compare to Alzamend Neuro?

Is ALZN or PTIX more profitable?

Do analysts prefer ALZN or PTIX?

Which has stronger earnings & valuation, ALZN or PTIX?

Do insiders & institutionals hold more shares of ALZN or PTIX?

Which has more risk & volatility, ALZN or PTIX?

Does the media prefer ALZN or PTIX?

Summary

How does Atrinsic compare to GeoVax Labs?

Do insiders & institutionals hold more shares of PTIX or GOVX?

Does the media refer more to PTIX or GOVX?

Do analysts recommend PTIX or GOVX?

Which has more risk and volatility, PTIX or GOVX?

Is PTIX or GOVX more profitable?

Which has better valuation & earnings, PTIX or GOVX?

Summary

How does Atrinsic compare to GRI Bio?

Is GRI or PTIX more profitable?

Which has better earnings & valuation, GRI or PTIX?

Does the media prefer GRI or PTIX?

Which has more volatility & risk, GRI or PTIX?

Do analysts prefer GRI or PTIX?

Do insiders & institutionals have more ownership in GRI or PTIX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PTIX vs. The Competition

Atrinsic Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools